用MDMA辅助疗法治疗严重抑郁症:原则证明研究
Tor-Morten Kvam1,2, Ivar W Goksøyr2, Justyna Rog2
1Institute of Clinical Medicine, University of Oslo, Norway.
概括
这项研究表明,3,4-甲基二氧化甲胺 (MDMA) 辅助治疗对于严重抑郁症 (MDD) 是安全的和可行的. 在患有MDD的参与者中,MDMA辅助疗法显著减少了抑郁症症状和功能障碍.
科学领域:
- 精神病学是一个精神病学.
- 临床心理学 临床心理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 3,4-甲基二氧化甲胺 (MDMA) 辅助疗法 (MDMA-AT) 已证明对创伤后应激障碍的疗效.
- 之前没有对MDMA-AT进行过重大抑郁障碍 (MDD) 的研究.
研究的目的:
- 探索MDMA-AT对MDD的原则证明和安全性.
- 提供MDMA-AT治疗MDD的初步疗效数据.
主要方法:
- 十二名患有中度至重度MDD的参与者接受了两个开放式MDMA疗程,隔1个月,结合心理治疗.
- 主要结局:蒙哥马利-阿斯伯格抑郁评分表 (MADRS) 的变化. 二次结果:希恩残疾量表 (SDS) 的变化.
- 使用描述性统计,威尔科克森签名等级测试和混合效应模型分析数据.
主要成果:
- 通过成功的招聘和保留来证明可行性.
- 从基线到治疗后8周的MADRS得分显著降低 (平均差异-19.3,P < 0.001).
- 与基线相比,SDS得分显著下降 (平均差异 -11.7,P = 0.001). 没有报告严重不良事件.
结论:
- 在MDD中,MDMA-AT满足了安全性和可行性的主要目标.
- 预先的疗效表明,抑郁症和功能障碍的显著减少.
- 需要进一步的随机对照试验来证实这些发现.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
373
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
373
Electroconvulsive Therapy
200
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
200
Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
Modeling in Therapy
152
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
152
Depressive Disorders: MDD and Dysthymia
224
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
224
Antidepressant Drugs: Overview
786
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
786


